Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Dietz J, Sarrazin C. Reply to: "Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings". J Hepatol 2021;75:254-255. [PMID: 33892009 DOI: 10.1016/j.jhep.2021.04.017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/14/2021] [Accepted: 04/14/2021] [Indexed: 12/04/2022]

For:	Dietz J, Sarrazin C. Reply to: "Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings". J Hepatol 2021;75:254-255. [PMID: 33892009 DOI: 10.1016/j.jhep.2021.04.017] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/14/2021] [Accepted: 04/14/2021] [Indexed: 12/04/2022]

Number

Cited by Other Article(s)

Karimi-Sari H, Rezaee-Zavareh MS, Falade-Nwulia O, Lim JK. Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection. J Hepatol 2022;77:1215-1217. [PMID: 35798132 DOI: 10.1016/j.jhep.2022.06.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/23/2022] [Revised: 06/11/2022] [Accepted: 06/20/2022] [Indexed: 12/04/2022]